TapewireFind a company

person · Reporting owner

Girin Pascal E R

Disclosed activity across 1 company

Tapewire entity
45183
SEC CIK
0001329811

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ClearPoint Neuro, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect110,623 Reported balance After 2026-05-19 transaction · row 1
1 source row

Row 1 · 2026-05-19 · Exercise / conversion · Acquired 12,417 · Balance 110,623

F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-05-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-19 · Exercise / conversion · Disposed 12,417 · Balance 0

F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 19, 2026 Filed May 21, 2026 20:30 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 Exercise / conversionRestricted Stock Units · Derivative 12,417 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-234565 · ownership.xml · derivative · entry 2

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,417 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Read SEC document
May 19, 2026 Filed May 21, 2026 20:30 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 Exercise / conversionCommon Stock 12,417 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-234565 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,623

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Read SEC document
April 01, 2026 Filed Apr 2, 2026 18:52 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 755 $9.10 $6,870.50
Disclosure

SEC source: 0001193125-26-139783 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,206

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 23:43 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 502 $13.68 $6,867.36
Disclosure

SEC source: 0001193125-26-002929 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,451

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2025.

Read SEC document
October 01, 2025 Filed Oct 2, 2025 23:06 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 315 $21.79 $6,863.85
Disclosure

SEC source: 0001193125-25-228831 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,949

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

Read SEC document
July 01, 2025 Filed Jul 2, 2025 20:53 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 523 $11.94 $6,244.62
Disclosure

SEC source: 0000950170-25-093132 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,634

F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025.

Read SEC document
May 22, 2025 Filed May 23, 2025 22:12 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantRestricted Stock Units · Derivative 12,417 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-077190 · ownership.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,417

Underlying: Common Stock · 12,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

Read SEC document
May 16, 2025 Filed May 19, 2025 21:07 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 Exercise / conversionRestricted Stock Units · Derivative 21,093 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-074543 · ownership.xml · derivative · entry 2

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Read SEC document
May 16, 2025 Filed May 19, 2025 21:07 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 Exercise / conversionCommon Stock 21,093 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-074543 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 00:21 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 525 $11.89 $6,242.25
Disclosure

SEC source: 0000950170-25-049818 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,018

F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2025.

Read SEC document
January 02, 2025 Filed Jan 3, 2025 21:45 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 406 $15.38 $6,244.28
Disclosure

SEC source: 0000950170-25-001287 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,493

F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2024.

Read SEC document
October 01, 2024 Filed Oct 2, 2024 20:22 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 557 $11.21 $6,243.97
Disclosure

SEC source: 0001285550-24-000113 · wk-form4_1727900535.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,087

F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2024.

Read SEC document
July 01, 2024 Filed Jul 2, 2024 21:21 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 1,333 $5.39 $7,184.87
Disclosure

SEC source: 0001285550-24-000086 · wk-form4_1719955307.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,530

F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 28, 2024.

Read SEC document
May 16, 2024 Filed May 17, 2024 20:25 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantRestricted Stock Units · Derivative 21,093 $0.00 $0.00
Disclosure

SEC source: 0001285550-24-000069 · wk-form4_1715977516.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,093

Underlying: Common Stock · 21,093 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders.

Read SEC document
May 14, 2024 Filed May 15, 2024 13:19 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 Exercise / conversionRestricted Stock Units · Derivative 17,153 $0.00 $0.00
Disclosure

SEC source: 0001285550-24-000057 · wk-form4_1715779184.xml · derivative · entry 2

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,153 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders.

F2 · derivative.expiration_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders.

Read SEC document
May 14, 2024 Filed May 15, 2024 13:19 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 Exercise / conversionCommon Stock 17,153 Not disclosed Not disclosed
Disclosure

SEC source: 0001285550-24-000057 · wk-form4_1715779184.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,197

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 01, 2024 Filed Apr 2, 2024 20:43 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 1,056 $6.80 $7,180.80
Disclosure

SEC source: 0001285550-24-000042 · wk-form4_1712090587.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,044

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 28, 2024.

Read SEC document
January 02, 2024 Filed Jan 3, 2024 16:56 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 1,058 $6.79 $7,183.82
Disclosure

SEC source: 0001285550-24-000005 · wk-form4_1704301006.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,988

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 29, 2023.

Read SEC document
October 02, 2023 Filed Oct 3, 2023 16:41 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 1,434 $5.01 $7,184.34
Disclosure

SEC source: 0001285550-23-000104 · wf-form4_169635125838802.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,930

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2023.

Read SEC document
July 03, 2023 Filed Jul 5, 2023 21:46 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 992 $7.24 $7,182.08
Disclosure

SEC source: 0001285550-23-000078 · wf-form4_168859355434556.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,496

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2023.

Read SEC document
May 25, 2023 Filed May 26, 2023 18:11 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantRestricted Stock Units · Derivative 17,153 $0.00 $0.00
Disclosure

SEC source: 0001285550-23-000064 · wf-form4_168512470141759.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,153

Underlying: Common Stock · 17,153 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders.

F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders.

Read SEC document
April 03, 2023 Filed Apr 4, 2023 20:56 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 851 $8.44 $7,182.44
Disclosure

SEC source: 0001285550-23-000037 · wf-form4_168064180220234.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,504

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2023.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 22:58 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 901 $7.97 $7,180.97
Disclosure

SEC source: 0001285550-23-000007 · wf-form4_167287312360999.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,653

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $7.97 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending December 30, 2022.

Read SEC document
October 03, 2022 Filed Oct 4, 2022 22:17 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 705 $10.19 $7,183.95
Disclosure

SEC source: 0001285550-22-000062 · wf-form4_166492182952022.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,752

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $10.19 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending September 30, 2022.

Read SEC document
July 01, 2022 Filed Jul 6, 2022 18:37 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 668 $12.63 $8,436.84
Disclosure

SEC source: 0001285550-22-000029 · wf-form4_165713264416431.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,047

F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $12.63 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending June 30, 2022.

Read SEC document
May 25, 2022 Filed May 27, 2022 20:30 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantStock Options (right to buy) · Derivative 6,179 $0.00 Strike: $9.71 $0.00
Disclosure

SEC source: 0001420506-22-001139 · doc4_1009.xml · derivative · entry 2

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,179

Underlying: Common Stock · 6,179 shares

Expires 2032-05-25

F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders.

Read SEC document
May 25, 2022 Filed May 27, 2022 20:30 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 9,269 $0.00 $0.00
Disclosure

SEC source: 0001420506-22-001139 · doc4_1009.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,379

F1 · price: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders.

Read SEC document
April 01, 2022 Filed Apr 5, 2022 21:08 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 847 $9.96 $8,436.12
Disclosure

SEC source: 0001171520-22-000237 · eps10157.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,110

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $9.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2022.

Read SEC document
January 01, 2022 Filed Jan 4, 2022 12:18 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 730 $11.54 $8,424.20
Disclosure

SEC source: 0001171520-22-000015 · doc4_990.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,263

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $11.54 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2021.

Read SEC document
October 01, 2021 Filed Oct 4, 2021 20:14 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 470 $17.92 $8,422.40
Disclosure

SEC source: 0001420506-21-001360 · doc4_970.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,533

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $17.92 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended October 1, 2021.

Read SEC document
June 30, 2021 Filed Jul 2, 2021 20:17 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 296 $20.26 $5,996.96
Disclosure

SEC source: 0001420506-21-000845 · doc4_938.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,063

F1 · price: 1.These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $20.26 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2021.

Read SEC document
June 25, 2021 Filed Jun 28, 2021 12:38 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantStock Options (right to buy) · Derivative 6,006 $0.00 Strike: $19.98 $0.00
Disclosure

SEC source: 0001171520-21-000265 · ownership.xml · derivative · entry 2

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,006

Underlying: Common Stock · 6,006 shares

Expires 2031-06-25

F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders.

Read SEC document
June 25, 2021 Filed Jun 28, 2021 12:38 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 3,003 $0.00 $0.00
Disclosure

SEC source: 0001171520-21-000265 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,767

F1 · shares: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders.

Read SEC document
March 31, 2021 Filed Apr 2, 2021 20:05 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 322 $19.57 $6,301.54
Disclosure

SEC source: 0001420506-21-000378 · doc4_920.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,764

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021.

Read SEC document
December 31, 2020 Filed Jan 4, 2021 23:37 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 379 $15.00 $5,685.00
Disclosure

SEC source: 0001420506-21-000012 · doc4_896.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,422

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020.

Read SEC document
September 30, 2020 Filed Oct 1, 2020 22:07 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 996 $5.71 $5,687.16
Disclosure

SEC source: 0001420506-20-001031 · doc4_856.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,063

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020.

Read SEC document
June 30, 2020 Filed Jul 2, 2020 17:32 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 1,570 $3.55 $5,573.50
Disclosure

SEC source: 0001171520-20-000288 · doc4_816.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,067

F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020.

Read SEC document
June 03, 2020 Filed Jun 17, 2020 20:07 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantStock Options (right to buy) · Derivative 15,000 $0.00 Strike: $4.13 $0.00
Disclosure

SEC source: 0001420506-20-000689 · doc4_810.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-03

F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders.

Read SEC document
March 31, 2020 Filed Apr 2, 2020 20:12 UTC ClearPoint Neuro, Inc. CLPT · Entity 2367 GrantCommon Stock 1,505 $3.57 $5,372.85
Disclosure

SEC source: 0001420506-20-000361 · doc4_794.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,497

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2020.

Read SEC document
December 31, 2019 Filed Jan 2, 2020 22:04 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 1,084 $4.96 $5,376.64
Disclosure

SEC source: 0001420506-20-000007 · doc4_780.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,992

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019.

Read SEC document
September 30, 2019 Filed Oct 1, 2019 20:07 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 1,226 $5.15 $6,313.90
Disclosure

SEC source: 0001534424-19-000270 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,908

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2019.

Read SEC document
June 28, 2019 Filed Jul 1, 2019 20:07 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 1,993 $3.17 $6,317.81
Disclosure

SEC source: 0001534424-19-000197 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,682

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.17 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 28, 2019.

Read SEC document
June 07, 2019 Filed Jun 10, 2019 20:07 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantStock Options (right to buy) · Derivative 15,000 $0.00 Strike: $3.25 $0.00
Disclosure

SEC source: 0001534424-19-000174 · ownership.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-07

F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2020 annual meeting of stockholders.

Read SEC document
March 29, 2019 Filed Apr 2, 2019 20:13 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 2,006 $3.15 $6,318.90
Disclosure

SEC source: 0001534424-19-000102 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,689

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2019.

Read SEC document
December 31, 2018 Filed Jan 2, 2019 22:13 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 4,294 $1.47 $6,312.18
Disclosure

SEC source: 0001534424-19-000012 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,683

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2018.

Read SEC document
September 28, 2018 Filed Oct 1, 2018 20:39 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 3,592 $1.76 $6,321.92
Disclosure

SEC source: 0001534424-18-000336 · ownership.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,389

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.76 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 28, 2018.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:06 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 2,668 $2.18 $5,816.24
Disclosure

SEC source: 0001534424-18-000239 · girin.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,797

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.18 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 29, 2018.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 12:48 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantStock Options (right to buy) · Derivative 15,000 $0.00 Strike: $2.18 $0.00
Disclosure

SEC source: 0001534424-18-000207 · girin.xml · derivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2019 annual meeting of stockholders.

Read SEC document
March 30, 2018 Filed Apr 2, 2018 20:53 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 1,696 $3.13 $5,308.48
Disclosure

SEC source: 0001534424-18-000111 · girin.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,129

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018.

Read SEC document
December 29, 2017 Filed Jan 26, 2018 21:05 UTC ClearPoint Neuro, Inc. MRIC · Entity 2367 GrantCommon Stock 2,273 $2.75 $6,250.75
Disclosure

SEC source: 0001534424-18-000028 · girin.xml · nonDerivative · entry 1

Girin Pascal E R · CIK 0001329811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,433

F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.75 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 29, 2017.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.